MedPath
HSA Approval

ROPIVACAINE-AFT SOLUTION FOR INJECTION 1% W/V

SIN15261P

ROPIVACAINE-AFT SOLUTION FOR INJECTION 1% W/V

ROPIVACAINE-AFT SOLUTION FOR INJECTION 1% W/V

June 8, 2017

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.
Licence HolderAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

EPIDURAL

Medical Information

N01BB09

ropivacaine

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

Elpen Pharmaceutical Co., Inc

Active Ingredients

Ropivacaine base 8.826 mg/mL eqv Ropivacaine hydrochloride

10 mg/mL

Ropivacaine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ROPIVACAINE-AFT SOLUTION FOR INJECTION 1% W/V - HSA Approval | MedPath